1-4 of 4
Jenny Qun Wu
Close
Sort by
Journal Articles

Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

Jacob D. Soumerai, Anthony R. Mato, Ahmet Dogan, Venkatraman Seshan, Erel Joffe, Kelsey Flaherty, Jason Carter, Ephraim P Hochberg, Jeffrey A Barnes, Audrey Hamilton, Jeremy S. Abramson, Connie Lee Batlevi, Matthew J. Matasar, Ariela Noy, Colette Owens, M. Lia Palomba, Anita Kumar, Tak Takvorian, Ai Ni, Morgan Choma, Chaya Friedman, Puja Chadha, Elizabeth Simkins, Jade Ruiters, Sidney Sechio, Daneal Portman, Natascha Nolet, Neena Mahajan, Rosalba Martignetti, Joanna Mi, Krista J Scorsune, Julia M Lynch, Brianne McGree, Stephanie Y Hughes, Clare Grieve, Lindsey E. Roeker, Meghan C. Thompson, P. Connor Johnson, Mikhail Roshal, Jane Huang, Juliana M.L. Biondo, Jenny Qun Wu, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz
Journal: Blood
Blood (2021) 138 (Supplement 1): 3753.
https://doi.org/10.1182/blood-2021-150961
Published: 2021
Journal Articles

Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

John F. Seymour, Jenny Qun Wu, Relja Popovic, Barbara Eichhorst, Peter Hillmen, Thomas J. Kipps, Anton W. Langerak, Carolyn Owen, Julie Dubois, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Fengjiao Dunbar, Yanwen Jiang, Brenda Chyla, Michelle Boyer, Maria Thadani-Mulero, Marcus Lefebure, Rosemary Harrup, Arnon P. Kater
Journal: Blood
Blood (2021) 138 (Supplement 1): 1548.
https://doi.org/10.1182/blood-2021-147731
Published: 2021
Journal Articles

Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate Is Slower Following Venetoclax-Rituximab (VenR): Results from a Minimal Residual Disease (MRD) Model from the Randomized Phase 3 Murano Trial

Arnon P. Kater, Tong Lu, Anton W. Langerak, Clemens Mellink, Brenda Chyla, Jenny Qun Wu, Michelle Boyer, Marcus Lefebure, Yanwen Jiang, John F. Seymour
Journal: Blood
Blood (2021) 138 (Supplement 1): 1551.
https://doi.org/10.1182/blood-2021-148612
Published: 2021
Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Arnon P Kater, MD PhD, Jenny Qun Wu, MS, Julie Dubois, Christopher R Bolen, PhD, Zoe J Assaf, PhD, Peter Hillmen, MD PhD, Barbara F. Eichhorst, MD, Eric F Eldering, PhD, Thomas J. Kipps, MD PhD, Anton W Langerak, PhD, Clemens Mellink, PhD, Anne-Marie Van Der Kevie-Kersemaekers, PhD, Carolyn Owen, MD, Brenda J Chyla, PhD, Elizabeth A Punnoose, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Yanwen Jiang, PhD, John F. Seymour, MBBS, PhD FRACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 356.
https://doi.org/10.1182/blood-2019-123678
Published: 2019